Scarica l'app Stockscreener
2.52
3.08%
-0.08
Dopo l'orario di chiusura:
2.53
0.010
+0.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.60
Aprire:
$2.66
Volume 24 ore:
5.81M
Relative Volume:
0.48
Capitalizzazione di mercato:
$1.00B
Reddito:
$241.53M
Utile/perdita netta:
$-389.92M
Rapporto P/E:
-2.0488
EPS:
-1.23
Flusso di cassa netto:
$-323.54M
1 W Prestazione:
+6.78%
1M Prestazione:
+5.00%
6M Prestazione:
+13.00%
1 anno Prestazione:
-52.81%
Intervallo 1D:
$2.50
$2.68
Intervallo di 1 settimana:
$2.42
$2.725
Portata 52W:
$1.6385
$6.09
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.52 | 1.03B | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Can Iovance Biotherapeutics Inc grow without dilutionJuly 2025 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 - The Manila Times
Iovance Biotherapeutics to Host Conference Call for Q4 and Full Year 2025 Financial Results on February 24, 2026 - Quiver Quantitative
Iovance Biotherapeutics to Report Fourth Quarter and Full - GlobeNewswire
Market Wrap: Will Iovance Biotherapeutics Inc benefit from green energy policiesCPI Data & Expert Curated Trade Setups - baoquankhu1.vn
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility - Yahoo Finance
Is It Time To Reconsider Iovance Biotherapeutics (IOVA) After Prolonged Share Price Weakness - Yahoo Finance
Iovance’s Amtagvi Data and Valuation Gap Refocus Investor Attention - Yahoo Finance
Does The Recent Share Price Slump Make Iovance Biotherapeutics (IOVA) Look More Attractive? - Sahm
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure - Insider Monkey
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Melanoma cell therapy shows 52% response when used earlier - stocktitan.net
Iovance Biotherapeutics Announces Promising Real-World Data for Amtagvi® in Advanced Melanoma Treatment - Quiver Quantitative
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma - GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Barclays Sticks to Their Buy Rating for Iovance Biotherapeutics (IOVA) - The Globe and Mail
Assessing Iovance Biotherapeutics (IOVA) Valuation As It Transitions To Commercial Stage With First Product Launch Plans - Sahm
Iovance down 18% warning it could be impacted by geopolitical instability, inflation - MSN
Former Iovance CEO Maria Fardis lands at AirNexis with $200 millionBizwomen - The Business Journals
She raised more than $1 billion for Iovance. Now, Maria Fardis has a new startup and a $200 million investment - The Business Journals
Performance Recap: Why is Iovance Biotherapeutics Inc stock going upJuly 2025 Opening Moves & Capital Efficiency Focused Strategies - baoquankhu1.vn
Trade Recap: Whats the beta of Iovance Biotherapeutics Inc stockOptions Play & Real-Time Sentiment Analysis - baoquankhu1.vn
Iovance Biotherapeutics Inc. (IOVA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Iovance Biotherapeutics (IOVA): Investor Outlook Reveals 217% Potential Upside - DirectorsTalk Interviews
Aug Reactions: Will Iovance Biotherapeutics Inc benefit from AI trendsJobs Report & Target Return Focused Stock Picks - baoquankhu1.vn
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.5%Should You Sell? - MarketBeat
Financial Investigation Sparks Potential Reforms at Iovance Biotherapeutics - StocksToTrade
Is Iovance Biotherapeutics Inc. showing insider buyingJuly 2025 Drop Watch & Low Risk Profit Maximizing Plans - mfd.ru
Activity Recap: Whats the beta of Iovance Biotherapeutics Inc stock2025 Historical Comparison & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Autologous Cell Therapy Market Size to Reach US$ 44.55 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Recap Report: Whats the beta of Iovance Biotherapeutics Inc stockGap Up & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 7.4% HigherStill a Buy? - MarketBeat
IOVA Shares Jump 8% — What’s Retail Expecting? - Stocktwits
Iovance Biotherapeutics Sets Stage for Global TIL Leadership with Stock Induction Moves - StocksToTrade
Short Squeeze: Can LANDP sustain its profitability2025 Risk Factors & Verified Short-Term Plans - baoquankhu1.vn
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Unpacking a Potential 210% Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Expected To Breakeven In The Near Future - 富途牛牛
How Investors Are Reacting To Iovance Biotherapeutics (IOVA) FDA Boost For Its TIL Cancer Platform - simplywall.st
Advanced Melanoma Pipeline Expands With 60+ Investigational Therapies and 55+ Active Developers, Reports DelveInsight - Barchart.com
Advanced Melanoma Pipeline Expands With 60+ Investigational - openPR.com
Bull Run: Is Iovance Biotherapeutics Inc showing insider buyingEarnings Performance Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Assessing Iovance Biotherapeutics (IOVA) Valuation After Clinical Trial Progress And New FDA Designations - Sahm
What drives Iovance Biotherapeutics Incs stock priceTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn
Trend Report: Will TNON benefit from seasonalityPortfolio Gains Summary & Stepwise Trade Execution Plans - baoquankhu1.vn
Dow Update: Can Iovance Biotherapeutics Inc deliver consistent EPS growthPortfolio Performance Report & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Why Iovance Biotherapeutics Stock Got Mashed on Monday - MSN
Analyst Boosts Iovance’s Price Target Amid Positive Market Moves - timothysykes.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Iovance Biotherapeutics Stock Surges Amid Strategic Moves - StocksToTrade
Is Iovance Biotherapeutics (IOVA) A Potential Opportunity After Multi Year Share Price Slide - Sahm
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):